Published in Vaccine Weekly, October 29th, 2003
As a result of general market conditions in the biotechnology industry, the financing terms available to ID Biomedical were unacceptable.
"When we filed our registration statement, our share price was $19.05. Since that time, we have seen a significant decline in the biotechnology sector. As a result, our valuation requirements were not met by the market and we believe offering shares at a discount to our already reduced October 2,  closing price would be simply unacceptable at this time to our current shareholders," stated Dr....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly